Memantin Goodwill

Memantine Hydrochloride, the active ingredient in Memantin Goodwill, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is employed to treat cognitive decline associated with Alzheimer’s disease in adult patients. The medication is indicated for patients with moderate to severe Alzheimer’s disease and is administered under medical supervision.

GNH USA supplies Memantin Goodwill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantin Goodwill, an NMDA receptor antagonist, is used in the management of Alzheimer’s disease.

- Alzheimer’s disease (moderate to severe): improves cognition and functional abilities in affected patients. - Alzheimer’s disease (mild to moderate): may help maintain daily living activities. - Behavioral symptoms of Alzheimer’s disease: may reduce agitation and aggression.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue - Confusion - Hypertension

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (rash, swelling, anaphylaxis) - Cardiac arrhythmias - Hepatic dysfunction - Psychosis or severe agitation - Neurotoxicity at high plasma concentrations

Memantin Goodwill requires careful consideration of patient‑specific factors before initiation.

- Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic disease: monitor liver enzymes regularly. - Concomitant NMDA antagonists: avoid additive neurotoxicity. - History of seizures: use with caution and monitor closely. - Elderly patients: start at low dose and titrate slowly. - Store below 25°C: keep in the original pack, protect from moisture.

Memantin Goodwill can interact with several drug classes; monitoring is essential.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity. - Other NMDA antagonists (e.g., ketamine): additive central nervous system effects.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish cognitive benefit. - CNS depressants (e.g., benzodiazepines): enhanced sedation. - Diuretics: possible alteration of plasma memantine levels. - Antihypertensives: monitor blood pressure for additive effects.